This site is for New Zealand healthcare professionals. If you are a patient, please click here.

Please enter your email address to view the content of this website.

Not a member? Register
You are here: Home / Foundation Medicine

Foundation Medicine

FoundationMedicine-logo.jpg

About Foundation Medicine®

Cancer care is undergoing transformation. Foundation Medicine is a world-leading molecular insights company that provides insights to physicians and their patients through Comprehensive Genomic Profiling. Each patient’s cancer is unique; the diagnosis of specific and individualised biomarker information helps connect patients to targeted therapies, immunotherapies or clinical trials – making personalised medicine a reality.

In New Zealand, Roche’s pharmaceutical division is the licensed distributor of FoundationOne® (for patients with solid tumours) and FoundationOne®Heme (for patients with sarcomas or haematological cancers including leukaemia, lymphoma and myeloma), offering Comprehensive Genomic Profiling services and decision support tools that may inform cancer treatment decisions.


Products

FoundationOne®

FoundationOne is a validated Comprehensive Genomic Profile for solid tumours. The test is designed to provide physicians with clinically actionable information to guide treatment decisions for patients based on the genomic profile of their disease. Test results provide information about clinically significant alterations, potential targeted therapies, available clinical trials, and quantitative markers of response for immunotherapy.

FoundationOne is validated to detect all classes of genomic alterations in more than 300 cancer-related genes, including select introns from more than 25 genes often rearranged or altered in solid tumours.

Technical Information and gene list

  • This document provides the following information:
    • Clinical background
    • Methods
    • Reporting
    • Current gene list

Specimen guidelines

  • These guidelines will help achieve successful genomic profiling

Publications

Cost

  • FoundationOne costs NZ$6300 (including GST) per profile.

Turn-around time

  • It typically takes 14 days from the time the tissue sample is received in Boston, USA for Foundation Medicine Inc. to analyse and prepare the customised FoundationOne® profile.
  • It may take up to 7 days to source and prepare a sample for shipment.


FoundationOne®Heme

FoundationOneHeme is a Comprehensive Genomic Profiling assay for hematologic malignancies and sarcomas. The test is designed to provide physicians with clinically actionable information to help with diagnostic subclassification, prognosis assessment, and targeted therapeutic selection. Test results provide information about clinically significant alterations, potential targeted therapies, available clinical trials, and quantitative markers that may support immunotherapy clinical trial enrolment.

FoundationOneHeme is validated to detect all classes of genomic alterations in more than 400 cancer-related genes. In addition to DNA sequencing, FoundationOneHeme employs RNA sequencing across more than 250 genes to capture a broad range of gene fusions, common drivers of hematologic malignancies, and sarcomas.

Technical Information and gene list

  • This document provides the following information:
    • Clinical background
    • Methods
    • Reporting
    • Current gene list

Specimen guidelines

  • These guidelines will help achieve successful genomic profiling.

Publications

Cost

  • FoundationOneHeme costs NZ$7890 (including GST) per profile.

Turn-around time

  • It typically takes 21 days from the time the tissue sample is received in Boston, USA for Foundation Medicine Inc. to analyse and prepare the customised FoundationOne®Heme profile.
  • It may take up to 7 days to source and prepare a sample for shipment.

igenz-logo.png

Partnership with IGENZ

We are pleased to be partnering with IGENZ to simplify the ordering process for clinicians and add value to the service here in New Zealand.

IGENZ is committed to delivering quality and ethical laboratory testing services and pursuing continuous improvement in technologies, communication and scientific knowledge.

To deliver Foundation Medicine products to New Zealanders, IGENZ will:

  1. Source, prepare and manage shipment of tissue samples
  2. Manage profile and testing issues should they arise
  3. Develop a New Zealand specific Supplementary Report to complement the individualised report curated by Foundation Medicine. This will provide localised information:
    • regarding medication availability and indications
    • on clinical trials recruiting within New Zealand and Australia


Prior to ordering a profile, the patient must provide consent for Foundation Medicine to conduct the comprehensive genomic profiling. It is also optional to provide consent for Foundation Medicine to use their de-identified test results for genomic research.

You can download a copy of the patient consent form here.


How to order

Order a profile at www.foundationmedicine.co.nz


New Users

Existing Users

1. Registration
Click Sign Up
Fill in your particulars and Register

brackets.png

1. Log in

Log in with Username (email address) and Password


brackets.png

2. Confirmation
Confirmation email will be sent
Verify your registration from the email

brackets.png

2. Order and Payment
Follow steps 3 and 4 on the left.
3. Order
Select a Profile and enter all fields
Within Hospital Details, add IGENZ as another physician to be notified
Physicians name: Amanda Dixon-McIver
Institution: IGENZ
Email address:info@igenz.co.nz

brackets.png


4. Payment
Select Payment Option
Download, print, and sign requisition form
Scan signed requisition form then email to IGENZ at info@igenz.co.nz along with pathology report


Enquiries

If you have questions regarding Foundation Medicine including specific questions regarding Reports and Supplementary Reports, please contact Roche NZ Medical Information:

Email: auckland.medinfonz@roche.com

Phone: 0800 276 243

Details to be provided:

  • TRF number (located at the top of the report)
  • Ordering clinician name and contact details
  • Details of enquiry


Resources

Precision Cancer Forum

A Global Oncology Experts’ Molecular Tumor Board

This online forum provides an interactive Q&A discussion and FAQs for Precision Oncology. More specifically it provides:

  • A dynamic discussion focused on precision-focused cancer therapeutics and molecular diagnostics
  • The opportunity to ask leading authorities about the role of Next Generation Sequencing (NGS) for clinical cancer care
  • The ability to discuss challenging cases in oncology and interpretation of genomic tests with world authorities

Access Precision Cancer Forum here.

iQ&A Genomic Profiling in Cancer

The Interactive Medical Intelligence Zone is a needs assessment-driven continuing medical education (CME) activity that utilizes international experts to provide evidence-based, guideline-consistent, and practice behaviour-changing information focused on critical and challenging topics in clinical medicine.

To ensure that the educational content of iQ&A programs will address practice gaps in clinical medicine, improve patient outcomes, and positively guide clinical practice strategies, international experts, usually in a roundtable format, will respond to questions submitted and/or generated by practitioners at CME mega-symposia, national congress, association meetings, or as part of on-line, enduring CME programs.

Questions reflecting the clinical needs of practitioners are then answered, analysed, and discussed by international experts, who provide evidence-based and clinically relevant guidance that is independent of commercial sources or the program sponsor.

Access iQ&A Genomic Profiling in Cancer here.